Induced Pluripotent Stem Cells Market to Grow with a CAGR of 9.60% through 2030
Increasing Prevalence of Chronic Diseases and Rising Geriatric Population are expected to drive the Global Induced Pluripotent Stem Cells Market growth in the forecast period, 2026-2030
According
to TechSci Research report, “Induced Pluripotent Stem Cells Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2030F”, the Global Induced Pluripotent Stem Cells Market stood at USD 1.45 Billion in 2024 and is anticipated to grow with a CAGR of 9.65% in the forecast
period, 2026-2030.
The accelerating prevalence of chronic, non-communicable diseases—including cardiovascular disorders, neurodegenerative conditions, diabetes, and cancer—continues to be a primary catalyst for growth in the global induced pluripotent stem cells (iPSCs) market. These complex conditions place an immense burden on global healthcare systems, and conventional therapies often fail to deliver durable or personalized outcomes. In this context, iPSCs offer a transformative alternative by enabling patient-specific treatment development, tailored to an individual’s unique genetic and cellular profile.
The personalized nature of iPSC-based therapies reduces the risk of immune rejection and improves overall therapeutic efficacy, making them a compelling choice for both clinicians and patients. These attributes are driving momentum in the development of regenerative therapies for high-impact diseases such as Parkinson’s, stroke, heart failure, and insulin-dependent diabetes. By facilitating the generation of disease-relevant cell types, iPSCs unlock targeted treatment opportunities that were previously unattainable using traditional modalities. At the same time, the biotechnology sector is intensifying its investment in iPSC R&D, driven by the platform's disruptive potential to reshape how diseases are modeled, understood, and treated. This surge in investment is not merely speculative—it reflects a structural shift in therapeutic strategy as drug developers increasingly prioritize cell-based platforms and precision medicine.
Breakthroughs in bioprocessing and cell reprogramming technologies are making iPSC production more scalable, consistent, and cost-efficient. This has made iPSC tools and therapies more accessible to researchers, clinical developers, and healthcare institutions, creating a positive feedback loop of adoption and innovation. The integration of artificial intelligence (AI) and high-throughput screening is also accelerating this trajectory. AI-powered analytics are being applied to large iPSC-derived datasets to identify promising drug candidates and predict their biological effects with unprecedented speed and accuracy. These advancements are streamlining drug discovery pipelines, improving decision-making, and reducing development costs—critical drivers for pharmaceutical and biotech stakeholders.
Global academic institutions and research organizations are rapidly expanding dedicated iPSC infrastructure, investing in advanced laboratories, biobanks, and quality-controlled production systems. These investments are laying the groundwork for next-generation research capabilities, enabling the creation of more sophisticated disease models and expediting translational research. Disease modeling using iPSCs has become significantly more advanced, with researchers now able to simulate rare genetic disorders and infectious diseases at the cellular level—providing deeper mechanistic insights and enabling targeted therapeutic discovery.
The market is witnessing a robust influx of capital from both public and private sectors. Government agencies are deploying grant funding to fuel iPSC innovation, while venture capital firms and pharmaceutical companies are increasing their stakes in emerging iPSC platforms. These investments are funding clinical trials, advancing manufacturing processes, and accelerating the development of commercial iPSC applications. Notably, the growing commitment from governments and biopharma reflects strategic recognition of iPSCs’ potential in addressing the rising healthcare demands of aging populations and chronic disease prevalence.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global Induced Pluripotent Stem Cells Market”
The Global
Induced Pluripotent Stem Cells Market is segmented into derived cell type,
application, end user, regional distribution, and company.
Based on
its end user, Research Institutions segment dominated the Global Induced Pluripotent Stem Cell Market during the forecast period. Academic and government-affiliated research institutions serve as the primary hubs for foundational iPSC research, including cellular reprogramming, lineage differentiation, and disease modeling. These institutions are often the originators of critical iPSC innovations, providing the early-stage discoveries that biotech and pharmaceutical companies later commercialize. Their focus on translational science and proof-of-concept studies makes research institutions essential for de-risking iPSC technologies before clinical and commercial deployment.
Research institutions benefit from robust funding pipelines, including national research grants, global health initiatives, and partnerships with industry stakeholders. Government agencies such as the National Institutes of Health (NIH), European Research Council (ERC), and Japan Agency for Medical Research and Development (AMED) have consistently funded iPSC programs housed within academic institutions. These funding channels reduce financial pressure on institutions while enabling sustained research into novel iPSC applications supporting market growth at its source. Universities and dedicated research centers typically have access to state-of-the-art facilities and specialized equipment for iPSC derivation, maintenance, and differentiation. Their scientific infrastructure is designed to handle high-complexity, cell-based experimentation that aligns well with the demands of iPSC technology. This infrastructure allows research institutions to operate at the forefront of scientific innovation, maintaining leadership in both quality and output of iPSC-based findings
Based on region Asia Pacific is poised to witness fastest market growth in the Global Induced Pluripotent Stem Cell Market. Several Asia Pacific countries particularly Japan, China, South Korea, and Singapore have positioned regenerative medicine and stem cell research as strategic national priorities. Governments are actively supporting iPSC research through targeted funding, favorable regulatory pathways, and public-private partnerships. Japan, for instance, is a global pioneer in iPSC research, being the birthplace of the technology under Nobel laureate Shinya Yamanaka. The Japanese government continues to invest heavily in clinical-grade iPSC lines and translational research through institutions like the Center for iPS Cell Research and Application (CiRA). China has launched multiple government-backed initiatives aimed at establishing leadership in stem cell therapeutics and iPSC manufacturing capabilities. Proactive government engagement is creating an innovation-friendly ecosystem that accelerates clinical translation and commercialization.
Asia Pacific is witnessing significant infrastructure development in the biomedical research and biomanufacturing sectors. Universities, academic medical centers, and biotech clusters across the region are increasingly equipped with state-of-the-art facilities for iPSC generation, quality control, and differentiation. Investment in specialized cell culture labs and iPSC core facilities is enabling the region to support high-volume, scalable R&D pipelines. Strategic hubs such as Singapore’s Biopolis, Seoul’s Bio-cluster, and Shanghai’s Zhangjiang Hi-Tech Park are becoming regional centers of excellence for cell and gene therapy research. World-class infrastructure is reducing barriers to entry and enabling Asia Pacific institutions to conduct competitive iPSC research and development on a global scale.
Major companies
operating in Global Induced Pluripotent Stem Cells Market are:
- Axol Bioscience Ltd.
- Cynata Therapeutics Limited
- Evotec SE
- Fate Therapeutics, Inc.
- FUJIFILM Cellular Dynamics, Inc.
- Ncardia
- LizarBio Therapeutics (Pluricell Biotech)
- Reprocell USA, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Takara Bio, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The global
induced pluripotent stem cells market is being driven by the increasing use of
stem cell therapies, the growing biotechnology industry, and the rising
prevalence of chronic diseases. iPSCs are cells that have been reprogrammed to
an embryonic-like state from adult cells. This makes them a valuable tool for
research and potential therapies, as they can be used to generate any type of
cell in the body. Besides, the increasing use of stem cell therapies is one of
the key drivers of the iPSCs market. Stem cell therapies are being developed
for a variety of diseases, including heart disease, stroke, diabetes, and
Parkinson's disease.
The biotechnology industry is investing heavily in iPSC research and
development, due to the potential of iPSCs to revolutionize the way we treat
diseases. New technologies are being developed to make it easier and more
efficient to produce and use iPSCs. This is making iPSCs more accessible to
researchers and clinicians, which is anticipated to boost market growth. ” said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Induced Pluripotent Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others), By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling), By End user (Research Institutions, Other) By Region & Competition 2020-2030F",
has evaluated the future growth potential of Global Induced Pluripotent Stem
Cells Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Induced Pluripotent
Stem Cells Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com